Ji Zhong-He, Peng Kai-Wen, Li Yan
Department of Peritoneal Cancer Surgery, Cancer Center of Beijing Shijitan Hospital affiliated to the Capital Medical University, Beijing 100038, China.
Transl Gastroenterol Hepatol. 2016 Sep 19;1:69. doi: 10.21037/tgh.2016.08.03. eCollection 2016.
Peritoneal carcinomatosis (PC) is one of the most common causes of death in gastric cancer patients. Intraperitoneal free cancer cells (IFCCs) play a very important role in forming PC, but the administration of intraperitoneal chemotherapy (IPC) and/or hyperthermic intraperitoneal chemotherapy (HIPEC) could be an effective treatment for IFCCs. This review focuses on the origin of IFCCs, the mechanism of PC formatting, the rationale of IPC/HIPEC, and the current clinical trials on IPC/HIPEC to treat advanced gastric cancer patients.
腹膜癌病(PC)是胃癌患者最常见的死亡原因之一。腹腔内游离癌细胞(IFCCs)在形成PC过程中起着非常重要的作用,但腹腔内化疗(IPC)和/或热灌注腹腔内化疗(HIPEC)可能是治疗IFCCs的有效方法。本综述重点关注IFCCs的起源、PC形成机制、IPC/HIPEC的理论依据以及目前关于IPC/HIPEC治疗晚期胃癌患者的临床试验。